As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
HOME > COMMENTARY
COMMENTARY
- Actos Bladder Cancer Risk Highlights Problems with Safety Measures in Japan
July 4, 2011
- Era of Competition Dawns in Market for AD Treatments
June 27, 2011
- Will Dialogue between PSJ, JAMS Accelerate Development of Switch OTC Drugs?
June 20, 2011
- Return to Full-bore Growth Strategy Risky for Taiyo Pharm
June 13, 2011
- Why the Same Mistake Repeated? -MSD's Promotion Code Violations
June 6, 2011
- GE Makers to Make Difficult Decision on Actos Generics due to Combination Patent
June 6, 2011
- Effects of Changes to Accelerate Approval to Be Seen from November
May 30, 2011
- Japan's Most Admired Pharma Companies in 2010
April 4, 2011
- Will New Disclosure GL Promote Industry-Academia Alliances?
March 28, 2011
- Use of Generics by Welfare Recipients
March 7, 2011
- Wholesalers' Profits Drop Sharply Putting Premium for New Drug Development in Peril
February 21, 2011
- Safety Measures Based on Common Medical Knowledge Questioned by Court: Iressa Affair
February 21, 2011
- Recent Topics in Promising Anticancer Therapeutics
January 17, 2011
- Development Race for Oral Anticoagulants Entering Final Stretch
October 11, 2010
- How to Eliminate Concerns about Safety of Liovel
October 4, 2010
- Will It Be Possible to Eliminate Unnecessary Equivalence Studies for Generics?
September 20, 2010
- Big Pharma Losing Flagships within a Few Years and Shifting Paradigm
September 13, 2010
- Prior Assessment System Is One Step Forward to Quicker NDA Review
August 2, 2010
- Industry Needs to Form Consensus on Premium with Med. Institutions
July 26, 2010
- Japan Should Promote Personalized Cancer Treatment
July 26, 2010
ページ
While grappling with sluggish revenues in Japan last year amid 1.7% negative market growth as put by IQVIA, mega pharma companies saw their upbeat oncology franchises increasingly buttress their businesses in the country, helping them soften the blows from generic…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…